Search clinical trials for: Biochemo bevacizumab then ipilimumab

Total 81 results

California Pacific Medical Center Research Institute

Completed

Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma (BBI)

Metastatic Melanoma

United States
Dana-Farber Cancer Institute
Bristol-Myers Squibb; Genentech, Inc.

Completed

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

Melanoma

United States
Gustave Roussy, Cancer Campus, Grand Paris

Completed

A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma (NIVIPIT)

Stage III/IV Melanoma

France
University Hospital, Lille
Bristol-Myers Squibb

Completed

Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases (IPI+RTS)

Melanoma | Brain Metastasis

France
Institut Claudius Regaud

Terminated

Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)

Melanoma

France
Italian Network for Tumor Biotherapy Foundation
Astex Pharmaceuticals, Inc.

Unknown

A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients (NIBIT-M4)

Metastatic Melanoma

Italy
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States
Sheba Medical Center

Terminated

Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients

A Combination of Adoptive T Cell Therapy and Ipilimumab Could Increase the Proportion of CR Patients, and Durability of Response

Israel
University of Utah

Terminated

Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma

Stage III or IV Melanoma

United States
Bristol-Myers Squibb

Terminated

A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U)

Tumor

Italy, United States, New Zealand
University of Utah
Bristol-Myers Squibb; Acrotech Biopharma Inc.

Withdrawn

Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation (BENEFIT)

Metastatic Adenocarcinoma
Bristol-Myers Squibb
JSS Medical Research Inc.

Completed

Ipilimumab 12-month Intensive Pharmacovigilance Protocol

Melanoma

Venezuela
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive

Prostate Cancer

Australia, United States, Chile, Spain, France, Italy, United Kingdom, Germany, Netherlands
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma

Melanoma

United States
Sun Yat-sen University

Unknown

Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC (SEQUENCE)

Non Small Cell Lung Cancer

China
Lawrence Fong
Bavarian Nordic

Terminated

Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer

Prostatic Neoplasms

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
European Organisation for Research and Treatment...

Terminated

Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer (CRUCIAL)

Inoperable œsophageal Cancer

Spain, France
Icahn School of Medicine at Mount Sinai
Bristol-Myers Squibb

Completed

Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

United States
University of Erlangen-Nürnberg Medical School

Completed

Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition (ST-ICI)

Metastatic Cancer

Germany
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma

United States
Bristol-Myers Squibb

Completed

Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection

Urothelial Carcinoma

United States
Bristol-Myers Squibb

Completed

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

Unresectable Stage III or IV Malignant Melanoma

United States, Peru, Norway, Italy, Sweden, Denmark, Israel
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself (CheckMate204)

Melanoma

United States
Federation Francophone de Cancerologie Digestive

Not yet recruiting

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy (TRIPLET)

Metastatic Cancer | Metastatic Tumor | HCC - Hepatocellular Carcinoma

France
University of Texas Southwestern Medical Center

Terminated

A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients

Melanoma

United States
Craig L Slingluff, Jr

Terminated

A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma (Mel62; 6PAC)

Melanoma

United States
Ardigen
National Center for Research and Development, Poland; The Institute of Bioorganic...

Unknown

Polish Microbiome Map

Melanoma | Healthy Volunteers | Metagenome | Immunotherapy | Microbiome

Poland
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors

Advanced Cancer

Japan
Bristol-Myers Squibb
National Cancer Institute (NCI)

Withdrawn

Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma

Melanoma (Skin)
Tirgan, Michael H., M.D.

Terminated

Therapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue

Keloid

United States
Accelerated Community Oncology Research Network
Eli Lilly and Company; Genentech, Inc.

Completed

Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC

Non-Small Cell Lung Cancer

United States
Roberto Pili
Bristol-Myers Squibb; Syndax Pharmaceuticals; Indiana University School of Medicine

Active, not recruiting

Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Hospital of Macerata

Recruiting

International Multicentric Study ARON-1

Metastatic Renal Cell Carcinoma (mRCC)

Italy
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients (OpACIN)

Stage III Skin Melanoma

Netherlands
OncoImmune, Inc.
National Cancer Institute (NCI); Huntsman Cancer Institute

Withdrawn

CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) (CINDI)

Metastatic Melanoma

United States
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Completed

Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab

Ovarian Cancer | Peritoneal Cancer | Fallopian Tubes Cancer

United States
Ludwig-Maximilians - University of Munich

Recruiting

Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma (PRIDE)

Glioblastoma

Germany
Bristol-Myers Squibb

Active, not recruiting

A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (CheckMate 143)

Recurrent Glioblastoma

Poland, United Kingdom, United States, Spain, Australia, Germany, Italy, Denmark, Belgium, France, Netherlands, Switzerland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
Melanoma and Skin Cancer Trials Limited

Not yet recruiting

Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases (BETTER)

Melanoma Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute

Completed

Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas

Malignant Glioma

United States
Bristol-Myers Squibb

Completed

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

Lung Cancer (NSCLC)

China, Germany, Singapore, Hungary, Korea, Republic of, Poland
Isala

Recruiting

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie (MINUTE)

Oncology | Infusion Reaction

Netherlands
Sidney Kimmel Comprehensive Cancer Center at Johns...

Completed

Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

Pancreatic Cancer

United States
Dutch Colorectal Cancer Group
Hoffmann-La Roche

Completed

The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer (CAIRO4)

Rectal Cancer | Colon Cancer | Primary Tumour

Netherlands, Denmark
Northwestern University
National Cancer Institute (NCI)

Completed

Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer

Pancreatic Cancer

United States
CytoVac A/S

Terminated

Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan

Glioblastoma Multiforme

Denmark
Dorte Nielsen
Danish Cancer Society

Withdrawn

FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer (IMMUNOX)

Metastatic Colorectal Cancer

Denmark
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Unresectable Melanoma | Mucosal Melanoma | Stage IV Uveal Melanoma AJCC v7

United States

3

Subscribe